CUSIP 52886X107COMLXEOQ4 2025
52 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Janus Henderson Group PLC | 5.51M | $54.67M |
| 2 | Ra Capital Management, L.P. | 5.00M | $49.65M |
| 3 | Blackrock, Inc. | 4.91M | $48.73M |
| 4 | Paradigm Biocapital Advisors LP | 4.76M | $47.30M |
| 5 | Vestal Point Capital, LP | 4.47M | $44.44M |
| 6 | Frazier Life Sciences Management, L.P. | 4.42M | $43.94M |
| 7 | Vanguard Group Inc | 3.89M | $38.67M |
| 8 | Citadel Advisors LLC | 3.77M | $37.48M |
| 9 |
| 4 | Feb 13, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.1% | 3.70M | SEC |
| 5 | Jan 30, 2026 | The Vanguard Group | 13G | 5.3% | 3.89M | SEC |
| 6 | Jan 29, 2026 | Affinity Asset Advisors, LLC | 13G/A | 7.1% | 5.22M | SEC |
| 7 | Jan 21, 2026 | Blackrock, Inc. | 13G | 6.7% | 4.89M | SEC |
| 8 | Dec 8, 2025 | Janus Henderson Group PLC | 13G/A | 10.0% | 7.29M | SEC |
| 9 | Nov 20, 2025 | Paradigm Biocapital Advisors LP | 13G | 5.0% | 92.13M | SEC |
| 10 | Nov 14, 2025 | Janus Henderson Group PLC | 13G/A | 11.3% | 6.11M | SEC |
See the full Schedule 13D/13G history for Lexeo Therapeutics Inc.
Unlock full history| Avoro Capital Advisors LLC |
| 3.30M |
| $32.77M |
| 10 | Affinity Asset Advisors, LLC | 3.20M | $31.78M |